Julie Russell Dilts joins HCRN as General Counsel
Julie Russell Dilts, JD, has joined the Hoosier Cancer Research Network (HCRN) team as General Counsel. Julie brings a wealth of expertise in various legal and regulatory areas, as well as a passion for the mission of HCRN. Before joining HCRN, Julie led the Quality & Regulatory Compliance team at Roche Diagnostics Corporation. In her […]
HCRN launches new website
Hoosier Cancer Research Network (HCRN) launched an updated website today with new features and a modernized design. The new website, developed in collaboration with THE PLAID AGENCY, provides ease of access to our most-visited content: our clinical trials and our network, as well a drop-down menu that allows site visitors to learn more about HCRN’s […]
Correlative analysis from HCRN GU16-260 study published in Cancer Discovery
Researchers participating in the Hoosier Cancer Research Network GU16-260 study have published a correlative analysis in Cancer Discovery. The analysis, led by David A. Braun, MD, PhD, of Yale Cancer Center; Catherine J. Wu, MD, of the Dana-Farber Cancer Institute; and Michael B. Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, found that the presence of […]
Five HCRN studies presented at ASCO GU 2025, with HCRN-GU16-243 as a rapid oral abstract
Hoosier Cancer Research Network (HCRN) is set to participate in ASCO GU 2025 in San Francisco from February 13-15, 2025, with HCRN-GU16-243 being presented as a Rapid Oral Abstract, and several other studies as poster presentations.
HCRN-LUN21-497 presented at SITC 2024
A Hoosier Cancer Research Network abstract, HCRN-LUN21-497, titled, “Results from a phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer,” was presented at SITC 2024 by Jeffrey Clarke, MD, of Duke University.
HCRN-GI23-643 presented at ASCO GI 2025
HCRN-GI23-643, titled, “Randomized Trial of Regorafenib in Combination with Pembrolizumab or Pembrolizumab Monotherapy for Patients with MSI-H Colorectal Cancer,” will be presented as a Trials in Progress poster at the American Society of Clinical Oncology® (ASCO) Gastrointestinal Cancers Symposium 2025 in San Francisco. This study is led by Ibrahim Sahin, MD, of UPMC Hillman Cancer Center.
HCRN-GU16-243 presented at SUO 2024
A correlative study related to the Hoosier Cancer Research Network (HCRN) clinical trial, HCRN-GU16-243, titled, “A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study,” was presented at SUO 2024 by Noah Hahn, MD, […]
